Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share from the same period last year. The company reported quarterly sales of $7.877 million which beat the analyst consensus estimate of $3.000 million by 162.57 percent. This is a 166.66 percent increase over sales of $2.954 million the same period last year.